MedTrace Logo

Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden

NCT05190146 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7203

Last updated 2024-12-13

No results posted yet for this study

Summary

The purpose of this study is to conduct a multi-country, multi-site, epidemiologic study designed to assess the proportion of interferon gamma release assay (IGRA) positivity, at site level, and to build capacity to conduct a future TB vaccine efficacy study.

Conditions

  • Tuberculosis, Pulmonary

Sponsors & Collaborators

  • Gates Medical Research Institute

    lead OTHER

Principal Investigators

  • Gates MRI · Gates Medical Research Institute

Eligibility

Min Age
15 Years
Max Age
34 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-20
Primary Completion
2023-09-11
Completion
2024-08-16

Countries

  • Bangladesh
  • Brazil
  • Democratic Republic of the Congo
  • India
  • Indonesia
  • Kenya
  • Mozambique
  • Peru
  • Philippines
  • South Africa
  • The Gambia
  • Uganda
  • Vietnam
  • Zambia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05190146 on ClinicalTrials.gov